What We Learn From Clinical Trials

PhRMA: April 4, 2013

A recent op-ed in Forbes offers a welcome rebuttal to misguided criticism of the conduct of clinical trials by the biopharmaceutical industry by refuting the notion that “medicine is broken” partly due to the hiding of “negative” clinical trial results.

First, it explains how even clinical trials that do not validate the premise that they were intended to evaluate are not necessarily “negative”:

Clinical studies that yield unexpected or unwanted results are seldom negative in the sense of revealing actual net harm to patients from the drug or medical device being tested; far more often and for a variety of reasons, a “negative” study simply fails to show that it’s effective for certain indications, or uses. Read more